

**PB 121 of 2024**

National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 29 October 2024

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 November 2024 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2— Amendments commencing 1 April 2025 12

National Health (Minimum Stockholding) Determination 2023 12

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024*.

 (2) This instrument may also be cited as PB 121 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 November 2024. | 1 November 2024 |
| 2. Schedule 1 | 1 November 2024. | 1 November 2024 |
| 3. Schedule 2 | 1 April 2025. | 1 April 2025 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 November 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amiodarone | Tablet containing amiodarone hydrochloride 200 mg | Oral | APO-Amiodarone | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | APO-Amitriptyline 10 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

3 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | APO-Amitriptyline 25 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APO-Amitriptyline 50 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atenolol | Tablet 50 mg | Oral | APO-Atenolol | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | BOSLEER | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | BOSLEER | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | Tracleer | between 1 April 2024 and 31 May 2024—0 months stock by reference to usual demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Calcitriol | Capsule 0.25 microgram | Oral | APO-Calcitriol | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Calcitriol | Capsule 0.25 microgram | Oral | Kosteo | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

8 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Celecoxib | Capsule 100 mg | Oral | NOUMED CELECOXIB | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Celecoxib | Capsule 200 mg | Oral | NOUMED CELECOXIB | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

9 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciprofloxacin | Tablet 250 mg (as hydrochloride) | Oral | APX-Ciprofloxacin | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Ciprofloxacin | Tablet 500 mg (as hydrochloride) | Oral | APX-Ciprofloxacin | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Ciprofloxacin | Tablet 750 mg (as hydrochloride) | Oral | APX-Ciprofloxacin | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |

10 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Diazepam | Tablet 2 mg | Oral | APO-Diazepam | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Diazepam | Tablet 5 mg | Oral | APO-Diazepam | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | APO-Diclofenac | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | APO-Diclofenac | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

11 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxsig | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Duloxetine | Capsule 30 mg (as hydrochloride) | Oral | Cymbalta | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Duloxetine | Capsule 60 mg (as hydrochloride) | Oral | Cymbalta | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

12 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | ENTECLUDE | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | ENTECLUDE | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

13 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Prozac 20 | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

14 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Furosemide | Oral solution 10 mg per mL, 30 mL | Oral | Lasix | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Furosemide | Oral solution 10 mg per ml, 30 ml | Oral | Lasix | (a) between 1 November 2024 and 31 March 2024—4 months stock by reference to usual PBS demand(b) after 31 March 2024—6 months stock by reference to usual PBS demand |

15 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ibuprofen | Tablet 400 mg | Oral | MEDICHOICE IBUPROFEN 400 mg | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

16 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan | Tablet 150 mg | Oral | Irbesartan GH | between 1 November 2024 and 28 February 2025—0 months stock by reference to usual demand |
| Irbesartan | Tablet 300 mg | Oral | Irbesartan GH | between 1 November 2024 and 28 February 2025—0 months stock by reference to usual demand |

17 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan | Tablet 75 mg | Oral | Karvea | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |

18 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Itraconazole | Capsule 100 mg | Oral | APO-Itraconazole | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

19 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Labetalol | Tablet containing labetalol hydrochloride 100 mg | Oral | Presolol 100 | between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lamotrigine | Tablet 100 mg | Oral | NOUMED LAMOTRIGINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 200 mg | Oral | NOUMED LAMOTRIGINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 25 mg | Oral | NOUMED LAMOTRIGINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Lamotrigine | Tablet 50 mg | Oral | NOUMED LAMOTRIGINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Lansoprazole | Capsule 30 mg | Oral | NOUMED LANSOPRAZOLE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

20 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Movicol | between 1 October 2024 and 31 October 2024—0 months stock by reference to usual demand |

21 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nifedipine | Tablet 30 mg (controlled release) | Oral | Addos XR 30 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Nifedipine | Tablet 60 mg (controlled release) | Oral | Addos XR 60 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

22 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | Acpio 15 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 30 mg (as hydrochloride) | Oral | Acpio 30 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | Acpio 45 | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

23 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 150 mg | Oral | Cipla Pregabalin | between 1 October 2024 and 28 February 2025—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 150 mg | Oral | NOUMED PREGABALIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Pregabalin | Capsule 25 mg | Oral | NOUMED PREGABALIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Pregabalin | Capsule 300 mg | Oral | NOUMED PREGABALIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Pregabalin | Capsule 75 mg | Oral | NOUMED PREGABALIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

24 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Riluzole | Tablet 50 mg | Oral | APO-Riluzole | between 1 September 2024 and 31 October 2024—0 months stock by reference to usual demand |

25 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Salbutamol | Nebuliser solution 5 mg (as sulfate) in 2.5 ml single dose units, 30 | Inhalation | Salbutamol Cipla | between 1 June 2024 and 30 November 2024—4 months stock by reference to usual demand. |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sertraline | Tablet 100 mg (as hydrochloride) | Oral | NOUMED SERTRALINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Sertraline | Tablet 50 mg (as hydrochloride) | Oral | NOUMED SERTRALINE | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Simvastatin | Tablet 10 mg | Oral | NOUMED SIMVASTATIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Simvastatin | Tablet 20 mg | Oral | NOUMED SIMVASTATIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |
| Simvastatin | Tablet 40 mg | Oral | NOUMED SIMVASTATIN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

26 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Telmisartan | Tablet 80 mg | Oral | NOUMED TELMISARTAN | between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand |

27 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Temazepam | Tablet 10 mg | Oral | APO‑Temazepam | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Viatris | after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together |

28 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valaciclovir generichealth | between 1 August 2024 and 31 October 2024—0 months stock by reference to usual demand |

29 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valproic acid | Tablet, crushable, containing sodium valproate 100 mg | Oral | Epilim | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |
| Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | after 31 November 2024— 4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together |

Schedule 2— Amendments commencing 1 April 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atropine | Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL | Injection | Atropine Injection (Pfizer) | 6 months stock by reference to usual PBS demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Baclofen | Tablet 10 mg | Oral | APO‑Baclofen | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Balsalazide | Capsule containing balsalazide sodium 750 mg | Oral | Colazide | 6 months stock by reference to usual PBS demand |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Budesonide | Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | Inhalation by Mouth | Pulmicort Turbuhaler | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Calcium | Tablet 600 mg (as carbonate) | Oral | Calci-Tab 600 | 6 months stock by reference to usual PBS demand |

4 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ferrous Sulfate | Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL | Oral | Ferro-Liquid | 6 months stock by reference to usual PBS demand |

5 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glucose and ketone indicator‑urine | Test strips, 50 (Keto‑Diastix) | For External Use | Keto‑Diastix | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual | Nitrolingual Pumpspray | 6 months stock by reference to usual PBS demand |

6 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Triglycerides - medium chain, formula | Oral powder 400 g (Lipistart) | Oral | Lipistart | 0 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Triglycerides, medium chain | Oil 500 ml (MCT Oil) | Oral | MCT Oil | 6 months stock by reference to usual PBS demand |